Physician profile
Morgan G Parker
NPI 1417987926
$4,143.85
in general payments reported to CMS, 2019-2025
28 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $357 · 2021: $557 · 2022: $465 · 2023: $446 · 2024: $735 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084 · Entertainment: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.13 |
| Entertainment | $107.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $444.39 | 2021-2025 | Rocklatan, Hydrus Microstent, Eysuvis |
| Sun Pharmaceutical Industries INC. | $366.93 | 2019-2025 | Cequa |
| New World Medical,INC. | $321.91 | 2021-2024 | Ahmed Glaucoma Valve, Clearpath, Streamline |
| Kala Pharmaceuticals, INC. | $297.69 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $267.44 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $251.21 | 2023-2025 | Xiidra, Vyzulta, Miebo |
| Allergan, INC. | $244.17 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $216.59 | 2021-2025 | Tecnis Iol, Tecnis Simplicity |
| Oyster Point Pharma, INC. | $213.19 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rxsight INC | $201.84 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Aerie Pharmaceuticals, INC. | $152.73 | 2019-2021 | |
| Thea Pharma INC. | $150.94 | 2024-2025 | Iyuzeh |
| Optos, INC. | $120.65 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Harrow Eye, LLC | $116.17 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $113.40 | 2024-2025 | Xdemvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $97.25 | 2019-2024 | Tearcare System |
| Astellas Pharma US INC | $93.77 | 2024-2025 | Izervay |
| Dompe US, INC. | $88.54 | 2024-2025 | Oxervate |
| Glaukos Corporation | $79.39 | 2019-2023 | |
| Ocular Therapeutix, INC. | $67.82 | 2022-2023 | Dextenza |
| Ivantis, INC | $67.78 | 2019 | |
| Abbvie INC. | $63.12 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.62 | 2020 | |
| Vantage Technology LLC | $18.60 | 2023 | |
| Biotissue Holdings INC. | $18.38 | 2023 | |
| Eyevance Pharmaceuticals LLC | $17.02 | 2020 | |
| Travere Therapeutics, INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.